Pramipexole CAS:104632-26-0

Pramipexole est dopamine agonist eiusdem generis medicinae ac Cabergoline. Praecipuum huius pharmaci propositum est in curatione morbi Parkinson. Pramipexole frequentissime sub notis nominum Sifrol invenitur, Mirapexin et Mirapex, quamquam genera quoque praesto sunt. Mirapex notissimus notissimus est a Boehringer Ingelheim Pharmaceuticals. Cum de Parkinson, Pramipexole praescribitur etiam syndrome crurum inquietorum curationi. Medicamentum etiam signa pollicens in curatione tristitiae bipolaris ostendit, quamvis numquam publice hunc titulum tenuit.

Pramipexole is a dopamine agonist that directly correlates with the prolactin hormone. As dopamine levels in the body go up, prolactin levels go down. It does this by having a direct effect on the dopamine D3 receptor. Although it also acts on the D2 receptor its affinity for the D3 receptor is seven times greater than any existing dopamine agonist.

The effect of Pramipexole on the D3 receptor has a strong impact on the neurological system, which is why it's used to treat Parkinson's disease and in some cases Alzheimer's disease. Through acting on the D3 receptor, Pramipexole also affects a man's sexual interest and activity. Prolactin is in part directly responsible for a man's refractory period, which refers to the time it takes to recover from sexual activity so that performance can occur again. By lowering prolactin through an increase in dopamine, Pramipexole can directly reduce the refractory period resulting in the ability to perform sexually more frequently.